Now that the MC is over $100M, VKTX will fall in the coverage universe of reputed biotech analysts. The really big ones like GS, Citi may not cover until $500M MC but I think we could see some decent analysts pick up coverage in coming months. A good PT from them will help the stock.
Investors are certainly getting aware of MDGL. As they research the company, they will stumble upon VKTX. I think big pharmas will also take note. NASH is a really hot space and big pharmas are spending like there's no tomorrow to have a presence in the field. I wouldn't be surprised if Viking catches the eyes of some of them.
News 
Market Data 
Discover 
